GANX vs. CMPS, FULC, SOPH, LRMR, ACB, FDMT, OCGN, AMLX, MOLN, and SLRN
Should you be buying Gain Therapeutics stock or one of its competitors? The main competitors of Gain Therapeutics include COMPASS Pathways (CMPS), Fulcrum Therapeutics (FULC), SOPHiA GENETICS (SOPH), Larimar Therapeutics (LRMR), Aurora Cannabis (ACB), 4D Molecular Therapeutics (FDMT), Ocugen (OCGN), Amylyx Pharmaceuticals (AMLX), Molecular Partners (MOLN), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry.
Gain Therapeutics vs.
Gain Therapeutics (NASDAQ:GANX) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, community ranking, valuation and risk.
In the previous week, COMPASS Pathways had 4 more articles in the media than Gain Therapeutics. MarketBeat recorded 5 mentions for COMPASS Pathways and 1 mentions for Gain Therapeutics. COMPASS Pathways' average media sentiment score of 0.59 beat Gain Therapeutics' score of 0.50 indicating that COMPASS Pathways is being referred to more favorably in the news media.
Gain Therapeutics has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.
COMPASS Pathways received 26 more outperform votes than Gain Therapeutics when rated by MarketBeat users. Likewise, 80.26% of users gave COMPASS Pathways an outperform vote while only 71.43% of users gave Gain Therapeutics an outperform vote.
COMPASS Pathways' return on equity of -63.85% beat Gain Therapeutics' return on equity.
Gain Therapeutics presently has a consensus target price of $7.25, suggesting a potential upside of 217.98%. COMPASS Pathways has a consensus target price of $33.60, suggesting a potential upside of 862.75%. Given COMPASS Pathways' higher possible upside, analysts plainly believe COMPASS Pathways is more favorable than Gain Therapeutics.
Gain Therapeutics has higher revenue and earnings than COMPASS Pathways. Gain Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
COMPASS Pathways beats Gain Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Gain Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gain Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GANX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free GANX Stock Alerts